← FDA DRUG APPROVALS

FDA ANDA · ANDA204159

TEMOZOLOMIDE

Sponsor: APOTEX

APPLICATION
ANDA204159
TYPE
ANDA
ORIGINAL APPROVAL
2018-07-05
LATEST ACTION
2024-05-16
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Discontinued

Products

TEMOZOLOMIDEDiscontinued
TEMOZOLOMIDE 180MG · CAPSULE · ORAL
TEMOZOLOMIDEDiscontinued
TEMOZOLOMIDE 100MG · CAPSULE · ORAL
TEMOZOLOMIDEDiscontinued
TEMOZOLOMIDE 5MG · CAPSULE · ORAL
TEMOZOLOMIDEDiscontinued
TEMOZOLOMIDE 250MG · CAPSULE · ORAL
TEMOZOLOMIDEDiscontinued
TEMOZOLOMIDE 140MG · CAPSULE · ORAL
TEMOZOLOMIDEDiscontinued
TEMOZOLOMIDE 20MG · CAPSULE · ORAL

Approval history

2024-05-16Labeling · Supplement 3 · standardAP
2021-12-22Labeling · Supplement 2 · standardAP
2020-07-18Labeling · Supplement 1 · standardAP
2018-07-05UNKNOWN · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →